PTH and hypoparathyroidism: The more frequently given reasons for preferring the trial treatment compared to their previous hypoparathyroidism treatment among those in the TransCon PTH group were treatment efficacy/symptom improvement (93.3%, n = 14) and frequency of administration/single daily dose (66.7%, n = 10):The ease of [the trial treatment] versus taking 15, 20 pills a day, and having to have a calcium all over your life of, in the office, in your purse, in the car.